Sign In
Buy IMNN
$2.10
-0.0400 (-1.87%)
At Close: Jun 03, 2026
Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript
05:31pm, Thursday, 13'th Nov 2025
Imunon, Inc. ( IMNN ) Q3 2025 Earnings Call November 13, 2025 11:00 AM EST Company Participants Stacy Lindborg - President, CEO & Director Douglas V. Faller - Chief Medical Officer Kimberly Graper - C
IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update
07:45am, Thursday, 13'th Nov 2025
R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advan
Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript
05:11pm, Monday, 10'th Nov 2025
Imunon, Inc. ( IMNN ) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study November 10, 2025 8:00 AM EST Company Participants Stacy Lindborg - President, CEO & Di
IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
01:30pm, Monday, 10'th Nov 2025
Webcast Recording and Symposium Slides Now Available LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-m
Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives Investors, stakeholders,
Investors and stakeholders invited to attend in person in New York City or via live webcast on Monday, November 10th at 8:00 a.m. ET
IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025
08:05am, Thursday, 06'th Nov 2025
LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Compa
Investor event in New York City to provide update on pivotal Phase 3 study of IMNN-001; offering in-person or virtual attendance on November 10, 2025
IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting
08:00am, Thursday, 30'th Oct 2025
Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 LAWRENCEVILLE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON , In
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
10:01am, Thursday, 23'rd Oct 2025
IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Ph
Investor event to provide update on pivotal Phase 3 study of IMNN-001 to be held in New York City on November 10, 2025 Program will feature presentations from ovarian cancer thought leaders, Phase 3 s
Company seeks strategic partners to advance novel PlaCCine technology LAWRENCEVILLE, N.J., Oct. 17, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company focused on developin
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
08:20am, Tuesday, 14'th Oct 2025
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway Company on
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-st
